{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:33Z","timestamp":1790391213783,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62220106006"],"award-info":[{"award-number":["62220106006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021B1515120013"],"award-info":[{"award-number":["2021B1515120013"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010673"],"award-info":[{"award-number":["2022A1515010673"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.eclinm.2023.102136","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T05:10:03Z","timestamp":1691125803000},"page":"102136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-3220","authenticated-orcid":false,"given":"Nian","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Miao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Fang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Ru","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Zhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6105-1149","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-0050","authenticated-orcid":false,"given":"Changqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-3794","authenticated-orcid":false,"given":"Hu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10192","key":"10.1016\/j.eclinm.2023.102136_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102136_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102136_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102136_bib4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.radonc.2013.10.020","article-title":"Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities","volume":"110","author":"Sun","year":"2014","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102136_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN Guidelines\u00ae insights: head and neck cancers, Version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"29","key":"10.1016\/j.eclinm.2023.102136_bib6","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1200\/JCO.21.00396","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study","volume":"39","author":"Hong","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102136_bib7","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00432-012-1219-x","article-title":"Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma","volume":"138","author":"Jin","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102136_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12935-019-0863-5","article-title":"The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"19","author":"Huang","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"36","key":"10.1016\/j.eclinm.2023.102136_bib9","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2023.102136_bib10","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102136_bib11","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102136_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cac2.12068","article-title":"A\u00a0phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors","volume":"40","author":"Wei","year":"2020","journal-title":"Cancer Commun"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102136_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102136_bib14","article-title":"Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study)","volume":"9","author":"Yang","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102136_bib15","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102136_bib16","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102136_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102136_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(11)70303-5","article-title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102136_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100313","article-title":"Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial","volume":"6","author":"Zhou","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102136_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102136_bib21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102136_bib22","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"34","key":"10.1016\/j.eclinm.2023.102136_bib23","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102136_bib24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jtho.2022.04.001","article-title":"Bevacizumab plus atezolizumab after progression on atezolizumab monotherapy in pretreated patients with NSCLC: an open-label, two-stage, phase 2 trial","volume":"17","author":"Lee","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102136_bib25","article-title":"Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)","volume":"10","author":"Seto","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102136_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2023.102136_bib27","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.934493","article-title":"Efficacy of PD-1 inhibitor combined with bevacizumab in treatment of advanced endometrial cancer patients with mismatch repair deficiency (dMMR)\/High-Level microsatellite instability (MSI-H)","volume":"28","author":"Liao","year":"2022","journal-title":"Med Sci Monit"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102136_bib28","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.eclinm.2023.102136_bib29","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102136_bib30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102136_bib31","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102136_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2023.102136_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01450","article-title":"Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study","volume":"41","author":"Ding","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102136_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10456-019-09670-4","article-title":"Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI","volume":"22","author":"Liang","year":"2019","journal-title":"Angiogenesis"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102136_bib35","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1007\/s00330-019-06198-5","article-title":"Value of blood oxygenation level-dependent MRI for predicting clinical outcomes in uterine cervical cancer treated with concurrent chemoradiotherapy","volume":"29","author":"Lee","year":"2019","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102136_bib36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jmri.28023","article-title":"Introducing a new biomarker named r2\u2217-BOLD-MRI parameter to assess treatment response in osteosarcoma","volume":"56","author":"Kim","year":"2022","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102136_bib37","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1148\/radiol.2483071407","article-title":"Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases","volume":"248","author":"Cui","year":"2008","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102136_bib38","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/1078-0432.CCR-17-1667","article-title":"Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase II correlative study","volume":"24","author":"Hui","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102136_bib39","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-10-3409","article-title":"A\u00a0Phase II study of pazopanib in Asian patients with recurrent\/metastatic nasopharyngeal carcinoma","volume":"17","author":"Lim","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.eclinm.2023.102136_bib40","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","article-title":"Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma","volume":"25","author":"Elser","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102136_bib41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdq629","article-title":"Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation","volume":"22","author":"Hui","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102136_bib42","article-title":"Analysis of plasma epstein-barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","author":"Chan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102136_bib43","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2023.102136_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2017.02.029","article-title":"Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment","volume":"77","author":"Zou","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2023.102136_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105200","article-title":"Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas","volume":"115","author":"Lin","year":"2021","journal-title":"Oral Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:40Z","timestamp":1762899700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023003139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"alternative-id":["S2589537023003139"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102136","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102136"}}